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Abstract
Introduction
Vitamin B3 has been shown to play an important role during embryogenesis. Specifically,
there is growing evidence that nicotinamide, the biologically active form of vitamin B3, plays
a critical role as a morphogen in the differentiation of stem cells to mature cell phenotypes,
including those of the central nervous system (CNS). Detailed knowledge of the action of
small molecules during neuronal differentiation is not only critical for uncovering mecha-
nisms underlying lineage-specification, but also to establish more effective differentiation
protocols to obtain clinically relevant cells for regenerative therapies for neurodegenerative
conditions such as Huntington’s disease (HD). Thus, this study aimed to investigate the
potential of nicotinamide to promote the conversion of stem cells to mature CNS neurons.
Methods
Nicotinamide was applied to differentiating mouse embryonic stem cells (mESC; Sox1GFP
knock-in 46C cell line) during their conversion towards a neural fate. Cells were assessed
for changes in their proliferation, differentiation and maturation; using immunocytochemistry
and morphometric analysis methods.
Results
Results presented indicate that 10 mM nicotinamide, when added at the initial stages of dif-
ferentiation, promoted accelerated progression of ESCs to a neural lineage in adherent
monolayer cultures. By 14 days in vitro (DIV), early exposure to nicotinamide was shown to
increase the numbers of differentiated βIII-tubulin-positive neurons. Nicotinamide
decreased the proportion of pluripotent stem cells, concomitantly increasing numbers of
neural progenitors at 4 DIV. These progenitors then underwent rapid conversion to neurons,
observed by a reduction in Sox 1 expression and decreased numbers of neural progenitors
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in the cultures at 14 DIV. Furthermore, GABAergic neurons generated in the presence of
nicotinamide showed increased maturity and complexity of neurites at 14 DIV. Therefore,
addition of nicotinamide alone caused an accelerated passage of pluripotent cells through
lineage specification and further to non-dividing mature neurons.
Conclusions
Our results show that, within an optimal dose range, nicotinamide is able to singly and selec-
tively direct the conversion of embryonic stem cells to mature neurons, and therefore may
be a critical factor for normal brain development, thus supporting previous evidence of the
fundamental role of vitamins and their metabolites during early CNS development. In addi-
tion, nicotinamide may offer a simple effective supplement to enhance the conversion of
stem cells to clinically relevant neurons.
Introduction
Human pluripotent stem cells are powerful contenders to alleviate a myriad of debilitating
brain-related degenerative disorders, directly as cell replacement therapies [1], or indirectly
through the development of in vitro models for the study of mechanisms underlying human
neural development, disease modelling, drug screening and neuroprotection assays [2]. How-
ever, clinical translations of stem cell candidates, such as embryonic stem cells (ESCs), can
only commence once important challenges have been adequately resolved and protocols are
improved to restrict stem cell proliferation linked to tumour formation, and to promote differ-
entiation of ESCs to higher and purer yields of desired cell phenotypes [3]. Furthermore,
understanding the mechanisms governing neural progenitor differentiation, neuronal fate
specification, maturation and survival of developing stem cell-derived neurons is crucial to
advance cutting-edge research in translational medicine.
Differentiation of neural progenitors into postmitotic neurons requires precise coordina-
tion of inductive signals required to inhibit self-renewal combined with signals that drive the
programme of terminal differentiation. Thus, knowledge of the effects and timing of inductive
molecules is fundamental for advancing prospective therapies to generate stem cell-derived
neuronal populations. In this regard, vitamins are well known to play crucial roles during early
neuronal development in embryogenesis, and a number of studies have shown that key signal-
ling proteins for vitamins are being expressed at the correct time and place to directly influence
neural development [4–6]. The biologically active metabolites of vitamin C (ascorbic acid),
vitamin D3 (calcitriol) and vitamin A (retinoic acid) are frequently included in differentiation
strategies to enhance the in vitro derivation of specific postmitotic subtypes from stem cells or
neural progenitors [7–17].
The identification of nicotinamide as a novel morphogen pointed to a critical, early role of
the vitamin B3 metabolite during the process of differentiation to influence cell fate specifica-
tion [18]. The early developmental role of nicotinamide is further supported by historical
examples of neurodegenerative pathology observed in motor neurons as a result of nicotin-
amide deficiency [19]. Further, in human Pellagra, nicotinamide and tryptophan deficiency
leads to range of symptoms including dermatitis, diarrhoea, dementia, depression and other
features of neurological disorders including Parkinsonism [20]. The ability of nicotinamide as
a differentiation agent to induce postmitotic neural phenotypes has been reported in various
Nicotinamide drives neuronal differentiation
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stem cells in vitro [12,15–17]. However, there is a paucity of information currently on the
potential of nicotinamide to drive ESC differentiation into neural and neuronal populations.
The present study describes a thorough investigation as to whether nicotinamide could
influence the conversion of mESCs undergoing neural differentiation to mature neurons,
using an adherent serum-free and factor-free monolayer differentiation protocol [21]. A
mESC cell line engineered to express a reporter of neural specification, Sox1GFP, was
employed here, to facilitate direct visualisation of the neural progenitor state in living cells
with fluorescence microscopy [21]. Thus, this advantageous feature of the Sox1GFP line
allowed, for the first time, a detailed investigation of the effects of nicotinamide, on ESC-
derived cell populations at any point during monolayer differentiation. Novel findings show
that nicotinamide functions as a potent signalling factor in brain development, and in a defin-
able dosage range and exposure time, accelerates the production and maturation of neurons.
Results
Nicotinamide accelerated neural lineage commitment of Sox1GFP
mESCs
Adherent monolayer cultures supplemented with nicotinamide at day 0 to day 2 and day 2 to
day 7 were analysed for the expression of markers of undifferentiated ESCs, early neural differ-
entiation and early neuronal development (Fig 1). To investigate whether nicotinamide could
promote mESC entry to the neural lineage in the monolayer culture system, changes in the
ESC marker protein, Oct4, were assessed. Nicotinamide added to undifferentiated Sox1GFP
knock-in reporter mESCs at the onset of differentiation (day 0) caused a significant reduction
in the number of Oct4-expressing colonies per field by day 2 (unpaired t test, t = 6.0; p<0.001;
3.3 ± 0.5in nicotinamide-treated vs. 10.2 ± 1.0 in controls; Fig 2(A) and 2(B)).
In accordance with other reports, there was a highly reproducible up-regulation of native
GFP expression in control cultures, driven by expression of the Sox1 gene by day 3–4 of mono-
layer differentiation [22,23]. Therefore, GFP expression was assessed at day 4, in cultures
treated with nicotinamide on days 0–2. The percentage of native GFP-labelled regions within
DAPI+ colonies was significantly enhanced in nicotinamide treated cultures by day 4,
Fig 1. Schematic diagram of time-course analysis of neural and neuronal differentiation in the
presence of nicotinamide. Undifferentiated cells were cultured as monolayers in N2B27 medium for
different durations to investigate whether nicotinamide would influence the conversion of
Oct4+undifferentiated stem cells (scale bar = 100 μm) to Sox1GFP neural progenitors (scale bar = 50 μm) and
thus drive differentiation toward βIII-tubulin+ neurons (scale bar = 50 μm). The potential of nicotinamide was
assessed using immunocytochemistry at different culture periods from days 2–14.
https://doi.org/10.1371/journal.pone.0183358.g001
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compared to controls (unpaired t test, t = 5.6; p<0.01; 38.1 ± 1.4% in nicotinamide treated vs.
7.6 ± 5.2% in control groups; Fig 2(C) and 2(D)).
Early application of nicotinamide induces a more potent effect on
neuronal differentiation
To establish the exact time-window of ESC differentiation where nicotinamide predominantly
acts on cells to increase neuronal production, adherent monolayer cultures supplemented with
nicotinamide at day 0 to 2, day 2 to day 7 and day 0 to day 7 were also analysed for the expres-
sion of βIII-tubulin marker. Consistent with results highlighting a rapid decline in the ESC
state and accelerated emergence of GFP+ progenitor cells, the expression of βIII-tubulin was
also up-regulated in nicotinamide-treated cultures as early as day 7 (the neural induction
stage) in this monolayer system. Nicotinamide administered from day 0 to 2 significantly pro-
moted the generation of immature neuronal populations (unpaired t test, t = 2.9; p<0.05;
6.8 ± 1.4% vs. 2.6 ± 0.3% in untreated conditions; Fig 2(E) and 2(F)). Therefore, these data
Fig 2. Nicotinamide accelerated neural specification of Sox1GFP mESCs. Nicotinamide treatment
significantly decreased Oct4+ pluripotent cells (A-B) and concomitantly increased GFP+ cells (C-D) at day 4,
suggesting enhanced neural lineage commitment. The effect of nicotinamide on immature neuron expression
was assessed during monolayer culture periods; (E-F) day 0–2, (G-H) day 2–7 and (I-J) day 0–7. Scale bar
100 μm applies to all low magnification images. ***p<0.001,**p<0.01, *p<0.05.
https://doi.org/10.1371/journal.pone.0183358.g002
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indicate that the processes of neural specification and neuronal differentiation were acceler-
ated, under the driving force of nicotinamide applied at the initial stages of ESC
differentiation.
Interestingly, addition of nicotinamide from day 0 of monolayer differentiation elicited a
more potent effect on neuronal differentiation by day 7. Monolayer cultures supplemented
with nicotinamide treatment from day 0 showed significantly enhanced yields of βIII-tubulin+
neurons (unpaired t test, t = 11.6; p<0.001; 15.2 ± 1.0% in day 0–7 treated vs. 3.5 ± 0.4% in
control groups; Fig 2(I) and 2(J)), in contrast to nicotinamide treatment between days 2 to 7,
which showed less effect (unpaired t test, t = 3.7; p<0.001; 7.3 ± 1.0% vs. 3.3 ± 0.6% in control
groups; Fig 2(G) and 2(H)).
Thus, given the direct effect of 10 mM nicotinamide at the early developmental stages of
ESC differentiation (i.e. day 0), the following experiments focused on monolayer cultures
treated with 10 mM nicotinamide at the initial stages of differentiation (i.e. day 0–7), and the
cells were further differentiated up to a total of 14 days.
Stem cell pluripotency was down-regulated when treated with
nicotinamide
The number of undifferentiated stem cell colonies per field, (determined by colonies express-
ing the stem cell marker Oct4 at day 14), was reduced by half when 10 mM nicotinamide was
added to cultures at the early phase of neural differentiation (i.e. days 0–7;unpaired t test,
t = 5.1; p<0.001; 3.2 ± 0.5 vs. 6.9 ± 0.5 in controls; Fig 3(A) and 3(B)). Therefore, these novel
findings indicate a beneficial role for nicotinamide to reduce the numbers of dividing cells in
adherent monolayer cultures by day 14.
We explored whether nicotinamide could impact on the phenotype of the remaining undif-
ferentiated colonies at day 14. The loss of the pluripotency regulator Oct4 was examined by
measuring colony area size (μm2) using Image-J software. Pluripotency was assessed within
individual DAPI-labelled colonies as the proportion of cells expressing the Oct4 protein; i.e. a
ratio of the region of red fluorescence (Oct4+) compared to blue fluorescence (DAPI+) within
a fixed area. Nicotinamide significantly decreased the size of Oct4-labelled colonies in cultures
treated between days 0 and 7. The percentage of Oct4-labelled areas within DAPI+ colonies
was significantly smaller in 10 mM nicotinamide treated cultures (unpaired t test, t = 3.6;
p<0.01; 17.5 ± 1.7% vs. 37.7 ± 4.2% in control conditions; Fig 3(C)). Cells treated between
days 7 and 14 did not show any significant differences in Oct4 expression (data not shown).
The mean area of DAPI+ and OCT4+colonies (μm2) was calculated for cultures treated at the
early stages differentiation (days 0–7) versus controls. DAPI-labelled colonies remained con-
stant in size (unpaired t test, t = 0.2; n.s.; 19680 μm2 ± 3625 in cultures with 10 mM nicotin-
amide vs. 20524 μm2 ± 1966 in control conditions; Fig 3(D)). In contrast, 10 mM
nicotinamide induced a rapid loss of pluripotency as evidenced by a significant reduction in
Oct4+ colony size (unpaired t test, t = 7.1; p<0.01; 2877 μm2 ± 625.2 vs. 7862 μm2 ± 317.1 in
controls; Fig 3(E)).
In summary, nicotinamide promoted earlier differentiation of mESCs from pluripotent
stem cells to a more mature developmental state, as evidenced by a decrease in Oct4 expression
following early nicotinamide exposure. Therefore, early supplementation of differentiating
ESC cultures with nicotinamide not only aids the elimination of potential tumorigenic cells
from cultures, but also promotes an accelerated loss of pluripotency, thereby speeding up cell-
cycle exit from the ESC state.
Nicotinamide drives neuronal differentiation
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Nicotinamide treatment decreases proliferation and accelerates
differentiation of progenitor cells towards a neuronal fate
The effect of nicotinamide on monolayer-derived Sox1GFP-expressing neural progenitors
(NPCs) was also assessed by quantifying GFP+ cells. Application of 10 mM nicotinamide
between days 0 and 7 significantly reduced the percentage of GFP-expressing NPCs by day 14
of differentiation (unpaired t test, t = 5.6; p<0.001; 12.8 ± 1.8% vs. 30.5 ± 2.6% in controls; Fig
4(A) and 4(B)). No significant differences in the percentage of GFP+ cells were found between
control and treatment conditions when nicotinamide was added at late differentiation stages
(unpaired t test, t = 0.8; n.s.; 32.5 ± 2.8% vs. 36.2 ± 3.7% in controls; Fig 4(A)–4(C)).
Within monolayer cultures, variations in the intensity of GFP expression was evident,
resulting in a spectrum from bright to low intensity GFP+ cells. It was hypothesised that cells
expressing higher levels of GFP represented true Sox1+ NPCs, and weaker GFP+ cells were
likely to be immature neuronal and glial cells that had down-regulated GFP expression, but
still possessed GFP protein, yet to be degraded. This is likely due to the longer half-life of the
GFP protein (~ 26 h), in contrast to theSox1 gene [24]. Therefore, to investigate the effect of
nicotinamide on intense and weak Sox1GFP+ neural progenitor populations, GFP+ cells were
scored for levels of reporter protein using OD measures. Data for OD values highlighted a
marked reduction in the relative levels of GFP expression in cells treated with 10 mM nicotin-
amide between days 0 and 7, compared to untreated cultures. Nicotinamide applied for the
first 7 days of differentiation almost completely eradicated “strong” Sox1GFP-expressing cells
(i.e. true Sox1+ NPCs) from cultures (ANOVA: F(12,36) = 17.18, p<0.0001). Significantly
more cells treated with nicotinamide from day 0–7 expressed low levels of Sox1GFP (0.2 units
fluorescence) compared with control cultures (0 mM nicotinamide applied at days 0–7 or
7–14; (Tukey’s multiple comparison t-tests: P<0.05, Fig 4(D)). Nicotinamide did not induce
significant differences in the relative levels of GFP expression in cells treated between days 7
and 14, further indicating that its action is differentiation stage-dependent.
In addition to neuronal differentiation, cultures were assessed for glial differentiation using
the antibodies: glial fibrillary acidic protein (GFAP) and neural/glial antigen 2 (NG2). Nicotin-
amide had no effect on the numbers of glial cells produced, at day 14 (Supplementary S1 Fig).
GFAP-expressing cells exhibiting long cellular projections similar to those of radial glial cells,
Fig 3. Early nicotinamide treatment accelerates stem cell differentiation. (A-B)Nicotinamide-treated
cultures (10 mM added from day 0–7) exhibited significantly lower numbers of Oct4+ colonies at day 14. (C)
Oct4+ colonies were smaller in area within DAPI+ colonies in cultures treated with nicotinamide. (D) DAPI
colonies were similar in area (μm2) across all treatment conditions. (E) Areas of Oct4+ colonies were markedly
reduced in cultures treated with 10 mM nicotinamide, suggestive of accelerated stem cell differentiation. Scale
bar 100 μm applies to all low magnification images. **p<0.01; ***p<0.001.
https://doi.org/10.1371/journal.pone.0183358.g003
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were detected at day 14, albeit in small numbers, in striking contrast with the number of βIII-
tubulin–expressing neurons generated at this time point. There was no significant effect on the
percentage of GFAP+ cells at day 14 in cultures of cells incubated with nicotinamide between
days 0 and 7 compared to control cultures, (unpaired t test, t = 1.0, n.s.) (0.3 ± 0.1% in nicotin-
amide treated cultures vs. 0.5 ± 0.2% in control conditions; Supplementary S1b Fig). Similarly,
there was no difference in NG2 expression when comparing differentiated cells treated with or
without nicotinamide (unpaired t test, t = 1.2, n.s.)(3.2 ± 0.5% in nicotinamide treated cultures
vs. 2.3 ± 0.6% in control conditions; Supplementary S1c Fig). The morphology of glial cells in
Fig 4. Early nicotinamide administration accelerates the conversion of neural progenitor populations to mature cell
types. (A-B) Early nicotinamide treatment (days 0–7) induced a significant decrease in the Sox1GFP+ population in comparison to
untreated cells. (A,C) Nicotinamide added between days 7 and 14 did not affect the population of Sox1GFP-expressing cells. (D)
Histogram showing the proportion of cells with different levels of Sox1GFP expression. Larger numbers of cells displayed weak
Sox1GFP expression in cultures that were exposed to 10 mM nicotinamide between days 0 and 7 (red bars), compared with
controls. (E-F) Addition of nicotinamide increased the population of GABAergic neurons from mESCs. Nicotinamide (10 mM)
added to media generated a significant increase in the percentage of the total GABAergic neuron population at day 14, compared
against the control untreated group. Some cells showed intense GABA immunoreactivity (yellow arrows) and some less strong
GABA expression (white arrow). Scale bar 50 μm applies to all high magnification images. ***p<0.001, **p<0.01.
https://doi.org/10.1371/journal.pone.0183358.g004
Nicotinamide drives neuronal differentiation
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the nicotinamide-treated cultures appeared normal, as expected in a mixed mature neural
culture.
These important data indicate that nicotinamide administration at the initial stages of dif-
ferentiation rapidly decreased the Sox1GFP+ NPC population, driving the neural progenitors
to become further differentiated to mature neurons, but had no influence on glial
differentiation.
Nicotinamide treatment enhanced the production of GABAergic neurons
from mESCs
Double immunofluorescence with anti-GABA and neuron-specific βIII-tubulin demonstrated
that the majority of Sox1GFP-derived neurons at day 14 in culture were immunopositive for
GABA, in line with other studies using the Sox1GFP knock-in 46C cell line [21,24].Therefore,
consistent with the higher proportion of βIII-tubulin neurons observed in nicotinamide
treated groups, 10 mM nicotinamide more than doubled the percentage of GABAergic neu-
rons of the total cell population labelled with DAPI, compared to un-treated cells (unpaired t
test, t = 8.5; p<0.001; 22.8 ± 1.2% vs. 10.7 ± 0.8%; Fig 4(E) and 4(F)). These data demonstrate
that Sox1GFP derived-mESCs differentiated with an early exposure to nicotinamide exhibit
higher yields of GABAergic neurons per culture.
Nicotinamide differentiation accelerated neuronal maturation in
GABAergic populations
The effect of nicotinamide on neurodevelopment and maturation was next investigated in
Sox1GFP mESC-derived GABAergic neuronal populations. Early neuronal development com-
mences with elongation of neurite processes followed by axon differentiation, dendritic
branching and synaptic formation. In this context, several types of GABAergic neuronal mor-
phologies were observed in monolayer cultures at day 14 of differentiation, i.e. GABAergic
neurons with short, medium and long neurite processes. Therefore, we assessed the effect of
nicotinamide on primary neurite outgrowth (i.e. length of the longest neurite), total neurite
outgrowth and the number of primary neurite branches per neuron.
In cultures treated with 10 mM nicotinamide, there was an upward trend in the proportion
of cells exhibiting “medium” (51.5 ± 1.3 vs. 47.8 ± 4.6 in controls; n.s.) and “long” (34.5 ± 2.9
vs. 15.2 ± 1.2 in controls; n.s.) neurite outgrowths, and therefore a significant reduction of the
proportion of GABAergic neurons displaying “short” primary neurite branches (14.0 ± 2.4 vs.
36.9 ± 4.2 in control conditions; p<0.001; Fig 5(A), 5(E) and 5(F)). Total neurite extent was
significantly increased in 10 mM nicotinamide cultures, compared to controls (unpaired t test,
t = 5.0; p<0.01; 86.05μm ± 4.0 vs. 61.11μm ± 3.0 in control groups; Fig 5(B)). Nicotinamide
treatment induced no significant changes in the number of primary neurites per neuron, com-
pared to untreated conditions (unpaired t test, t = 0.2; n.s.; 1.5 ± 0.1 vs. 1.5 ± 0.1 in control
groups; Fig 5(C)). Overall, these data suggest that nicotinamide was functioning to exert a
neurite growth-promoting action on young neuronal subtypes.
Further, GABAergic-expressing neurons exhibited differences in immunofluorescence
intensities post-staining with a primary antibody against GABA in monolayer cultures, result-
ing in a spectrum from weak to strong fluorescence. Cells expressing higher levels of immu-
nostaining are likely to represent more mature GABAergic neuronal subtypes, since strong
staining reflects more neurotransmitter content [25]. Therefore, to further investigate the
effect of nicotinamide on the maturation of GABAergic neurons, individual cell bodies were
scored for levels of immunofluorescence using OD measures and cells were categorised as
either ‘weak’ (OD 0.1 units) or ‘strong’ (OD 0.2 units) expressers.
Nicotinamide drives neuronal differentiation
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In agreement with the rapid maturation effect on neurite outgrowth, we observed a sub-
stantial increase in the proportion of GABAergic cells displaying higher neurotransmitter con-
tent within neuronal cell bodies. Analysis indicated an upward trend in the percentage of
neurons expressing intense GABA immunoreactivity, in cultures differentiated with 10 mM
nicotinamide (0.6 ± 0.0 vs. 0.5 ± 0.1 in control conditions; Fig 5(D)). Correspondingly, there
was a downward trend in the percentage of weak-expressing GABAergic neurons (0.4 ± 0.0 vs.
0.5 ± 0.1 in control conditions; Fig 5(D)).
Thus, Sox1GFP-derived neurons differentiated with nicotinamide between days 0 and 7
underwent neuronal morphogenesis earlier than cells induced with N2B27 medium alone.
These findings are consistent with the accelerated differentiation of mESCs to mature neurons
in the presence of nicotinamide.
Fig 5. Nicotinamide enhanced neuronal maturation in GABAergic populations. (A and E) The
proportion of 46C-derived cells displaying “short” primary processes was significantly decreased in cultures
exposed to 10 mM nicotinamide between days 0 and 7, concomitant with an obvious increased trend for
“longer” neurite processes, compared with controls (F). (B) Total length of neurites was significantly increased
in the presence of nicotinamide. (C) There was no difference in the number of primary neurites per neurons
between controls and nicotinamide-stimulated conditions. (D) An upward trend in the proportion of mESC-
derived cells displaying “strong” levels of GABA expression was demonstrated in cultures exposed to 10 mM
nicotinamide, which correlated with a downward trend in “weaker”-expressing GABAergic cells, compared
with control conditions. ***p<0.001, **p<0.01, *p<0.05. Micrographs show morphologies of GABA+ neurons
differentiated in control conditions (E), or cultures treated with 10 mM nicotinamide (F). Scale bar = 100 μm.
https://doi.org/10.1371/journal.pone.0183358.g005
Nicotinamide drives neuronal differentiation
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Discussion
This novel study reports that nicotinamide is sufficient to induce accelerated neural specifica-
tion from mESCs which further progressed to form GABAergic neuronal populations with
enhanced efficiency and maturity. Results obtained in this study show fundamental effects of
nicotinamide during the initial phases of ESC development, rather than at later stages of neu-
ronal differentiation [26]. Within 2 days of culture, nicotinamide had dramatically reduced the
number of Oct4-expressing pluripotent colonies and increased GFP fluorescence, thereby sug-
gesting that nicotinamide accelerated the conversion of mESCs to a neuroectoderm fate. Previ-
ous findings reported by Griffin et al. demonstrated that treatment of mESC (46C Sox1GFP
reporter cell line) monolayer cultures with nicotinamide at the early onset of development
decreased the total number of cells in cultures, resulting in a greater ratio of neurons to non-
neuronal cells [26]. Specifically, by day 14 in this study, nicotinamide treatment (from day
0–7) reduced the populations of undifferentiated cells and Sox1GFP+ progenitors, in addition
to reducing Oct4 and GFP expression in the cultures concomitant with enhanced expression
of βIII-tubulin, indicative of accelerated neuronal differentiation. Thus, this marked reduction
in distinct cell populations forms a mutually supportive body of data compatible with the pre-
vious data showing reduction of the total cell population at this time point. The cellular mecha-
nisms of nicotinamide in this regard are currently unknown. Therefore, further studies are
required to determine whether nicotinamide promotes inhibition of proliferation, and/or
whether nicotinamide induces cell death in specific cell populations. In this context, Vaca et al
found that nicotinamide could cause an 80% reduction in ESC proliferation [12], supporting
the former mechanism of action, whilst Idelson et al found that prevention of apoptosis in neu-
ral populations, rather than augmentation of their proliferation resulted in enhanced RPE dif-
ferentiation [15]. It is interesting to note that addition of nicotinamide from day 0 of
monolayer differentiation elicited a more potent effect on neuronal differentiation by day 7,
which promoted significantly enhanced yields of βIII-tubulin+ neurons. In contrast, nicotin-
amide induced a less marked effect on neural induction between days 2 and 7, implying that
the inductive role of nicotinamide may function during a narrow time window prior to or at
the stage of Sox1 expression during mESC differentiation. This data is in line with recent
observations that increased nicotinamide-N-methyl transferase (NNMT) activity may retain
embryonic stem cells in their naïve state, through regulation of epigenetic events, by creating
low levels of NNMT’s substrates S-adenosylmethionine and nicotinamide, leading to a subse-
quent reduction in histone methylation [27]. Furthermore, this early and robust effect suggests
that nicotinamide may be acting at the initial stages of ESC differentiation to influence the
transition of mESCs into neuroectoderm or indeed driving a switch from neural progenitors
to neurons in the differentiating cells. Similarly, the vitamin A derivative, RA has been shown
to regulate the proliferation-to-differentiation switch [28]. Specifically, RA has been reported
to promote differentiation and inhibit cell proliferation by directing cell cycle arrest in ESCs.
With particular relevance to the findings discussed in this study, early administration of RA to
differentiating adherent mono-cultures was found to restrict the proliferation of Sox1+ neu-
roectodermal precursors, resulting in enhanced neurite outgrowth and βIII-tubulin expres-
sion. In the present study, nicotinamide significantly reduced the percentage of GFP+ cells,
concomitant with a decrease in the number of actively proliferating Sox1GFP+ NPC cells. As
far as we are aware, this is the first report to demonstrate that the vitamin B3 metabolite may
be influencing a similar switch to RA—that is a neural proliferation-to-differentiation switch
from neural progenitors to neurons.
In this study, it is therefore reasonable to hypothesise that the initial higher frequency of
Sox1GFP+neural progenitors in monolayer cultures may be due to enhanced viability, or
Nicotinamide drives neuronal differentiation
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conversion of ESCs to neural progenitor cells during the early stages of development. In this
regard, one study showed that prevention of apoptosis was one of the mechanisms mediating
the promotion of neural specification by nicotinamide. Nicotinamide was shown to reduce cell
death of human ESC-derived NPCs upon neural induction, via inhibition of PARP, thereby
enhancing neutralization [29]. However, it is important to note that higher doses of nicotin-
amide (20 mM) induced cytotoxic effects on cells within 3 days of application [26]. This is in
agreement with other differentiation studies that also found that high doses of the active
metabolites of vitamin A (retinoic acid: 10−6μM) and vitamin C (ascorbic acid: 500–5000 μM)
had obvious negative effects on cell survival [8,23]. In this context, review papers published by
Williams et al propose a hypothetical link between a hypervitaminosis B3 state and modern
disease phenomena, resulting from a modern Western diet abundant in meat and vitamin sup-
plements [30,31]. Excess nicotinamide has been linked with lower levels of dopamine when
administered postnatally to mice (potentially through Sirt1 inhibition) [32]; and neurodegen-
eration in the Parkinsonian brain [33]. Conversely, some doses of nicotinamide have been
shown to be broadly neuroprotective in mouse models of MPTP-induced Parkinson’s [34],
implying that levels of this vitamin require tight regulation in order to support and sustain
normal neuronal functioning.
By day 14 of monolayer differentiation, early nicotinamide treatment (from day 0–7) had
reduced both Oct4 and GFP expression in the cultured cells. Two quantitative methods of
pluripotency: quantification of Oct4 immunoreactive colonies; and measurement of Oct4-la-
belled areas within DAPI stained colonies, both revealed a significantly reduced Oct4+ pluripo-
tent stem cell population in cultures at day 14. Nicotinamide supplementation also reduced
the Sox1GFP+ NPC numbers at day 14 of the monolayer protocol. Taken with previous find-
ings that nicotinamide increases the number of ßIII tubulin+ neurons at day 14 [26], itis there-
fore reasonable to conclude that, in the presence of nicotinamide, more NPCs differentiated
into neurons earlier. Interestingly, the majority of cells treated with nicotinamide showed uni-
formly weaker GFP expression. Thus, our findings are in support of previous evidence where
nicotinamide has been shown to eliminate Oct4+ dividing cells and progenitor cells from plu-
ripotent stem cell cultures, thereby speeding up differentiation into clinically relevant lineages
[15–17]. Data reveal that the GFAP protein and the early OPC marker, NG2, were expressed
in very few cells of the Sox1GFP-derived cultures at day 14; constituting less than 5% of the
total cell population. In addition, mature GFAP+ cells displaying characteristic large flattened
cell bodies were absent from monolayer cultures at this time-point. Thus, it is reasonable to
conclude that day 14 of monolayer differentiation might be too early to assess for the effect of
nicotinamide on glial fate, in line with previous reports in the literature.
It has been reported that neural progenitor formation and neuronal fate specification are
two closely linked processes occurring during ESC differentiation, which may be instructed by
the same signals [35]. GABAergic neurons are of particular interest for cell transplantation due
to their degeneration in the neostriatum which underlies the neuropathology of HD. In this
study, under control conditions, the vast majority of neuronal cells produced by monolayer
culture were GABA+, reflecting similar findings in other studies using Sox1GFP-derived cul-
tures [21,24,36]. Results reveal that nicotinamide treatment of mESCs led to a significant
increase in the proportion of the total cell population that were GABAergic neurons, highlight-
ing the potential of nicotinamide as a useful candidate in future protocols for generating
GABAergic populations.
Several reports support a role for nicotinamide in cellular maturation and differentiation
processes [37,38].In this study, nicotinamide treatment led to enhanced neurite elongation
and a tendency towards increased levels of neurotransmitter content within the cell bodies of
GABA-expressing neuronal subpopulations, therefore indicative of an accelerative effect on
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the maturation of mESC-derived neurons. We did not observe any aberrant cell phenotypes in
nicotinamide-treated cultures, suggesting that there are no untoward effects of nicotinamide,
i.e. the cells appear to be normal, and equivalent of a more mature neuronal culture. These
important findings provide crucial evidence that under serum-free and factor-free conditions,
enhanced neural subtype commitment and neuronal morphogenesis were predominantly due
to the independent effect of nicotinamide, applied during the early stages of stem cell differen-
tiation (i.e. day 0–7). These findings strongly suggest that nicotinamide could be applied to
current neuronal protocols during the early stages of neural conversion, in combination with
factors known to enhance neuronal phenotypes and to promote subtype specification. In this
regard, to fully determine the effects of nicotinamide on GABA differentiation, future work
should focus on the effects of nicotinamide in conjunction with ventralising factors using Shh
or an agonist, purmorphamine, which are necessary to promote the emergence of a forebrain
phenotype from ESCs [39], or indeed with RA which has been shown to function as a key
GABAergic differentiation signal in the basal ganglia circuitry [40].
Currently, the challenge in ESC biology to advance the potential of pluripotent stem cell
sources is to establish criteria for determining effective differentiation. Thus our work is highly
relevant to translate effective laboratory cell-based protocols to patients in clinical trials, open-
ing up the possibility of applying nicotinamide as a differentiation agent to aid the conversion
of stem cells to GABAergic neurons, helping to increase the efficiency of this process and the
safety of the cells produced.
Methods
All reagents used in this study were from Sigma, UK unless specified otherwise.
Embryonic stem cell culture
The mESC line 46C (a kind gift of Professor Meng Li, Neuroscience and Mental Health
Research Institute, Cardiff University, UK) carrying a green fluorescent protein knock-in
reporter targeted to the Sox1 promoter (transiently expressed during the neural progenitor
stage) was used throughout this study. mESCs were cultured in Glasgow Modified Eagles
Medium (Invitrogen, UK) with the addition of 10% FCS, 0.1 M β-mercaptoethanol, 1 mM L-
glutamine, 10 mM non-essential amino acids, 100 mM sodium pyruvate and 100 U/ml leukae-
mia inhibitory factor. Undifferentiated cells were routinely passaged every two days re-plating
at a density of 1 x 106 cells/cm2. mESCs were maintained on 0.1% gelatin-coated tissue culture
plastic at 37˚C in a 5% CO2 incubator.
Neural differentiation
Monolayer neural differentiation was based on a previous protocol using the 46C line estab-
lished by Ying et al [21]. Briefly, for neural induction, undifferentiated mESCs were plated at a
density of 9 x 104 cells/cm2 per well of a 0.1% gelatin-coated 6-well dish (day 0). N2B27 serum-
free medium (5 ml) consisting of a 1:1 ratio of DMEM/F12 (Invitrogen) and Neurobasal
media (Invitrogen) containing 0.5% N2 (Fisher Scientific, Loughborough, UK), 1% B27
(Fisher Scientific), 200mM L-glutamine and 0.1M β-mercaptoethanol was added to each well.
The medium was refreshed every alternate day. On day 7, single cells (3 x 104) were replated in
30 μl N2B27 medium on 13 mm glass coverslips (Fisher Scientific) pre-treated with poly-L-
lysine (PLL) (10 μg/ml) and laminin (2 μg/ml) in 24-well plates. After 4–6 h of incubation, the
wells were flooded with 500 μl of N2B27 medium, which was refreshed every other day until
day 14. During this 14-day period, cells were treated with the biologically active metabolite nic-
otinamide (10 mM), added to the base medium between either days 0 and 7 or days 7 and 14.
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Two additional culture periods with nicotinamide were also investigated: day 0 to 2 and day 2
to 7. Control groups were not treated with nicotinamide.
Cell sample analysis
To perform a comprehensive time-course analysis of the effect of nicotinamide on the progres-
sion of mESCs through neural induction and neuronal differentiation, immunocytochemistry
using fluorescent antibodies was carried out (Fig 1). Quantitative analysis techniques included
cell counts, optical density (OD) measures and area measurements for pluripotent colonies.
Immunofluorescence staining
Differentiated cells were fixed with 4% paraformaldehyde (PFA) for 20 min at 4˚C. Fixed cells
were washed three times with Tris buffered saline (TBS) for 5 min. Cells were blocked against
non-specific binding and permeabilised with 0.02% Triton X-100 and 5% normal goat serum
(NGS) (PAA, The Cell Culture Company, Somerset, UK), for 1 h at room temperature (RT).
Primary antibodies diluted in 1% NGS blocking buffer were added to cultured cells overnight
at 4˚C. Negative primary controls consisted of cells treated with blocking buffer without the
addition of primary antibodies. The next day, three TBS washes were applied to the cells for 5
min followed by incubation with fluorescent dye-conjugated secondary antibodies, diluted to
1:300 in 1% NGS blocking buffer, for 2 h at RT. Primary and secondary antibodies and dilu-
tions are reported in S1 Table. Cultures were washed three times with TBS for 5 min. Cover-
slips were mounted onto microscope slides using Vectashield hardset mounting medium
containing 4’, 6-diamidino-2-phenylindole (DAPI) (Vector Labs, Peterborough, UK) to coun-
terstain cell nuclei, before visualisation the following day.
Cell quantification
Cell samples were visualised using fluorescence microscopy (Nikon Eclipse 80i microscope;
Nikon UK Limited, Kingston upon Thames, UK) and images acquired using a Hamamatsu
ORCA camera (Hamamatsu Photonics UK Limited, Welwyn Garden City, UK). NIS-Elements
imaging software, version BR 3.2 (Nikon UK Limited) was used to manually quantify positive
antibody labelling in DAPI-stained cultures. Independent experiments were replicated three
times and three to four coverslips per group were counted within an experiment. Specific cell
populations were analysed by capturing six to eight random fields per coverslip. Data obtained
represent an average of approximately 50 DAPI-labelled cells per field of view. Clusters con-
taining dense populations of neural progenitor and neuronal cells were excluded from data
collection, since these cell networks were not countable.
Cell morphology analysis
Morphometric analyses were conducted to assess the extent of neuronal differentiation in the
presence of nicotinamide. Neuronal cells were photographed from eight to ten random fields
per coverslip from three independent experiments using a high power objective lens (i.e. x 40
lens). Neuronal cells within cell clusters were omitted from morphometric analysis. Four mor-
phological parameters were investigated: (1) measurement of neurotransmitter content within
neuronal cell bodies (soma) using OD measures; (2) number of primary neurite branches; (3)
length of longest neurite (μm), and (4) total neurite extent (μm). Neuronal processes greater
than two cell diameters in length were considered as true neurites and neurites of labelled cells
were manually traced using the ImageJ plug-in NeuronJ (version 1.4.2; NIF). Neurite length
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was defined as the distance from the soma to the tip of the longest primary neurite and the
combined lengths of all neurites per cell were defined as total neurite length.
Optical density
OD measures were obtained to determine levels of protein expression of specific neuronal
populations derived from Sox1GFP mESCs, using ImageJ image analysis software (version
1.45s; NIH). Cell samples were captured at fixed exposure settings using a Hamamatsu ORCA
camera with NIS Elements imaging software. Cells located within clusters were excluded from
OD analyses. OD values were evaluated by converting each colour image to grayscale and cali-
brated using an optical density step tablet. OD readings were then corrected for the
background.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 5.00 (GraphPad Software
Inc., La Jolla, California, USA). Data plotted on graphs is expressed as mean ± standard error
of the mean (SEM). An unpaired two-tailed t test was used to compare two sets of data. A level
of p<0.05 was used as a limit for statistical significance.
Supporting information
S1 Fig. Treatment of adherent cultures with nicotinamide elicited no effect on glial differ-
entiation. (A) Immunofluorescence images of glial populations generated from mESC-derived
monolayer cultures, showing immunostaining with antibodies specific to the astrocyte marker,
GFAP and the OPC marker, NG2. GFAP-expressing cells with leading processes and elongated
bodies were observed at day 14 of monolayer differentiation, and NG2-positive cells possessed
multiple processes, representative of their morphology in vivo. Cell nuclei counterstained with
DAPI (blue). Scale bar = 50 μm. (B) GFAP+ and (C) NG2+ cells were detected in cultures at a
very low percentage. No significant effects on glial expression were observed following treat-
ment of cultures with 10 mM nicotinamide between days 0–7.
(TIF)
S1 Table. List of antibodies used for immunofluorescence studies.
(TIF)
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